Comparative Pharmacology
Head-to-head clinical analysis: SIROLIMUS versus ZORTRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIROLIMUS versus ZORTRESS.
SIROLIMUS vs ZORTRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sirolimus is an immunosuppressant that forms a complex with FKBP12, which inhibits the mechanistic target of rapamycin (mTOR), a key regulator of cell cycle progression and proliferation. This inhibition blocks signal transduction from cytokine and growth factor receptors, thereby suppressing T-cell activation and proliferation.
Inhibits mammalian target of rapamycin (mTOR) by binding to FKBP-12, blocking cell cycle progression from G1 to S phase, thereby suppressing cytokine-driven T-cell proliferation.
Loading dose of 6 mg orally on day 1, followed by 2 mg orally once daily; or 3 mg orally on day 1, followed by 1 mg orally once daily. Maintenance dosing adjusted to achieve trough concentrations of 4-20 ng/mL. For de novo renal transplant recipients: 6 mg loading dose then 2 mg/day.
1.5 mg orally twice daily, administered with cyclosporine and corticosteroids.
None Documented
None Documented
Clinical Note
moderateSirolimus + Digoxin
"Sirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemsirolimus + Digoxin
"Temsirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateSirolimus + Digitoxin
"Sirolimus may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemsirolimus + Digitoxin
"Temsirolimus may decrease the cardiotoxic activities of Digitoxin."
Terminal half-life approximately 57-63 hours in adults, allowing once-daily dosing; longer in hepatic impairment.
Terminal elimination half-life is approximately 10-15 hours in renal transplant patients. In de novo liver transplant patients, half-life is ~13 hours. The effective half-life supports twice-daily dosing.
Primarily fecal (91%) with minimal renal excretion (2.2% as metabolites).
Primarily fecal (~78%) with <2.5% excreted unchanged in urine. Small amount via biliary elimination.
Category D/X
Category C
Immunosuppressant
Immunosuppressant